Posted by Michael Wonder on 05 Apr 2023
Caribou Biosciences announces FDA granted fast track designation to CB-011, an allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma
4 April 2023 - CaMMouflage Phase 1 trial for CB-011 enrolling patients with relapsed or refractory multiple myeloma at dose level 1.
Caribou Biosciences today announced that the US FDA has granted fast track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma.
